Endometriosis is a prevalent chronic gynecological disease that poses significant challenges for treatment due to its extensive lesions, diverse morphology, unknown etiology, and tendency for recurrence. In the early 21st …
Women with endometriosis, an inflammatory disease, are at increased risk of cardiovascular disease and demonstrate impaired microvascular endothelial function, characterized by reduced nitric oxide (NO)-mediated vasodilation. In some clinical cohorts, …
A 62-year-old otherwise healthy Caucasian female patient presented to the emergency department with a one-day history of severe abdominal pain, accompanied by nausea and non-bloody emesis. She did not report …
Tetramethylpyrazine (TMP) has been confirmed to suppress inflammation in endometriosis (EMs). Herein, this study investigated whether and how TMP affected NLRP3 inflammasomes and oxidative stress in EMs. After establishment of …
Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever, serositis, and arthritis. In women, FMF attacks can sometimes be triggered by the menstrual cycle. Once diagnosed, prophylactic …
A 55-year-old woman with a history of severe endometriosis, followed at our center for 16 years due to multiple episodes of horizontal binocular diplopia, was diagnosed with recurrent paresis of …
Background: Inflammation and immune cell dysfunction are critical facilitators of endometriosis pathophysiology. Macrophages are renowned for stimulating lesion growth, vascularization, innervation, and pain generation. By combining macrophages and endometriotic cells, …
Metabolic syndrome (MS), a cluster of cardiometabolic disorders, and sexual dysfunction are two conditions that impact a large proportion of the general population. Although they can occur independently, they are …
The prevalence of dysmenorrhea, the pain while menstruating, is high. Although most cases are benign, there should be a high suspicion of other etiologies such as endometriosis with recurrent episodes. …
Elagolix sodium salt is the first marketed orally active non-peptide gonadotropin-releasing hormone receptor antagonist (GnRHR-ant) for the management of hormone dependent diseases, such as endometriosis and uterine fibroids. Despite its …